{
  "run_id": "RUN_20260204_132700_1fed028ce5fb",
  "timestamp": "2026-02-04T15:31:32.850717",
  "document": "03_Protocol_ALXN1720-oMG-303.pdf",
  "document_path": "/Users/frederictetard/Projects/ese/gold_data/PAPERS/03_Protocol_ALXN1720-oMG-303.pdf",
  "total_candidates": 1038,
  "total_validated": 85,
  "total_rejected": 0,
  "total_ambiguous": 0,
  "heuristics_counters": {
    "recovered_by_stats_whitelist": 0,
    "recovered_by_country_code": 0,
    "recovered_by_hyphen": 0,
    "recovered_by_direct_search": 1,
    "recovered_by_llm_sf_only": 13,
    "blacklisted_fp_count": 10,
    "common_word_rejected": 13,
    "context_rejected": 0,
    "form_filter_rejected": 70,
    "trial_id_excluded": 0
  },
  "abbreviations": [
    {
      "short_form": "MGFA",
      "long_form": "Myasthenia Gravis Foundation of America",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 2,
      "context_text": "urulimab study in gMG showed that gefurulimab met the primary and all secondary endpoints, with participants achieving complete terminal complement inhibition, defined as serum free C5 < 0.5 t1g/mL over the treatment period in patients with gMG. Approximately half of incident MG cases present with muscle weakness restricted to ocular muscles known as oMG or Myasthenia Gravis Foundation of America (MGFA) Class | (Garcia Estévez, 2020; Hendricks, 2019; Mercelis, 2023; Santos, 2016). MGFA Classes II — IV extend the disease continuum and represent gMG of increasing severity. However, the disease mechanism for oMG is similar to gMG.",
      "lexicon_source": null,
      "lexicon_ids": null
    },
    {
      "short_form": "PKAS",
      "long_form": "PK Analysis Set",
      "confidence": 0.95,
      "field_type": "DEFINITION_PAIR",
      "page": 17,
      "context_text": "Set (FAS) All randomized participants who receive at least 1 dose of study ntervention. Participants will be analyzed as randomized. Per-Protocol Set (PPS) All FAS participants without important protocol deviations that are likely to impact efficacy during the RCT Period. The PPS will be fully defined in the SAP prior to database lock. Participants will be analyzed as randomized. PK Analysis Set (PKAS) All randomized participants who receive at least 1 dose of study intervention and have at least 1 evaluable postbaseline PK concentration. PD Analysis Set (PDAS) All randomized participants who receive at least 1 dose of study ntervention and have at least 1 evaluable postbaseline PD data point. Safety Set (SS) All randomized participants who receive at least 1 dose of study ntervention. Particip",
      "lexicon_source": null,
      "lexicon_ids": null
    },
    {
      "short_form": "PDAS",
      "long_form": "PD Analysis Set",
      "confidence": 0.95,
      "field_type": "DEFINITION_PAIR",
      "page": 17,
      "context_text": "AS participants without important protocol deviations that are likely to impact efficacy during the RCT Period. The PPS will be fully defined in the SAP prior to database lock. Participants will be analyzed as randomized. PK Analysis Set (PKAS) All randomized participants who receive at least 1 dose of study intervention and have at least 1 evaluable postbaseline PK concentration. PD Analysis Set (PDAS) All randomized participants who receive at least 1 dose of study ntervention and have at least 1 evaluable postbaseline PD data point. Safety Set (SS) All randomized participants who receive at least 1 dose of study ntervention. Participants will be analyzed according to the study ntervention they received. Immunogenicity Analysis All randomized participants who receive at least 1 dose (full or p",
      "lexicon_source": null,
      "lexicon_ids": null
    },
    {
      "short_form": "DQRMP",
      "long_form": "DESIGN QUALITY RISK MANAGEMENT PLANNING",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 40,
      "context_text": "Protocol Concept Sheet ALXN1720-oMG-303/D6783C00001 APPENDIX 1. DESIGN QUALITY RISK MANAGEMENT PLANNING (DQRMP) OUTPUT",
      "lexicon_source": null,
      "lexicon_ids": null
    },
    {
      "short_form": "MGII",
      "long_form": "Myasthenia Gravis Impairment Index",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 45,
      "context_text": "18 Sep 2025 Risk Category Risk Description Risk Response (Accept/Mitigate) Discuss at rDRC (Yes/No) Efficacy RISK 1: Variable symptoms in ocular | Risk 1. Mitigate No MG RISK 2: Incorrect administration order (PRO before exam) at Baseline and Week 12. RISK 3: Missing data on MGII (Myasthenia Gravis Impairment Index) item scores and total scores (ocular or generalized) at critical time points (Day 1 and Week 12). If more than 3 items are missing for the same assessment, the assessment may be invalid. Train and certify raters. Train patients and caregivers on PRO tool use to ensure accurate reporting over the recall period. Discussion: It was noted that while the symptoms are subjective to the patient, the Pat",
      "lexicon_source": null,
      "lexicon_ids": null
    },
    {
      "short_form": "HCPs",
      "long_form": "Healthcare Professionals",
      "confidence": 0.95,
      "field_type": "DEFINITION_PAIR",
      "page": 49,
      "context_text": "RISK 2: Viscosity differences pose a_ | Risk 2: Mitigate risk during the RCT to OLE transition | The dose at the transition from RCT to OLE is administered by HCP (Week 12) Discussion: Patients remained blinded during RCT. Viscosity differences pose a risk during the RCT to OLE transition where patients may receive mixed active and placebo syringes. It was explained that Healthcare Professionals (HCPs) administer these doses to prevent patients from feeling differences, thus maintaining blinding. Mitigations include HCP administration at transition to address viscosity differences. RISK 3: BIAS: Inconsistent Risk 3: Mitigate assessments for MGII exam ocular Raters will be trained and certified. score, for the same eye or both eyes. Standardize MGII assessment protocols across sites with detaile",
      "lexicon_source": null,
      "lexicon_ids": null
    },
    {
      "short_form": "IFU",
      "long_form": "instructions for use",
      "confidence": 0.95,
      "field_type": "DEFINITION_PAIR",
      "page": 51,
      "context_text": "Protocol Concept Sheet ALXN1720-oMG-303/D6783C00001 Risk Category Risk Description Risk Response (Accept/Mitigate) Discuss at rDRC (Yes/No) change-Clear instructions for use (IFU) tailored for different age groups, especially adolescents who are less reliant on caregivers. there were concerns about the complexity of the current study due to the mixed population (pediatric and adult). Caregivers manage younger participants, while adults and adolescents may self-administer independently, increasing risks of non-compliance or errors)",
      "lexicon_source": null,
      "lexicon_ids": null
    },
    {
      "short_form": "HBCAB",
      "long_form": "hepatitis B core antibody",
      "confidence": 0.9,
      "field_type": "GLOSSARY_ENTRY",
      "page": 34,
      "context_text": "HBCAB: hepatitis B core antibody",
      "lexicon_source": null,
      "lexicon_ids": null
    },
    {
      "short_form": "PPS",
      "long_form": "Per Protocol Set",
      "confidence": 0.95,
      "field_type": "DEFINITION_PAIR",
      "page": 16,
      "context_text": "The Full Analysis Set (FAS) will be the primary population used for the analysis of all efficacy endpoints for the RCT Period. Supplemental per protocol analyses for primary and secondary efficacy endpoints will be performed based on the Per Protocol Set (PPS) in the same manner as done for the FAS. Safety analyses will be performed on the Safety Set (SS).",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "PRO",
      "long_form": "Patient-reported outcomes",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 4,
      "context_text": "The difference between treatment groups in the mean change from Baseline in the MGII (PRO) ocular score at Week 12 will be assessed.",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "IPD",
      "long_form": "Important Protocol Deviation",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 46,
      "context_text": "e of disallowed medications (other complement inhibitors, FeRni’s, B-cell-depleting therapies): OMG SOC; B cell depleting therapies in past or present collected and that “If more than 3 items are missing for the same assessment, the assessment may be invalid” tSDV; Document incomplete collection as Important Protocol Deviation (IPD). Discussion: Highlighted past issues in the GA trial where incomplete data collection led to invalid results, stressing the need for accuracy, especially at baseline, due to the short, randomized control period. Additional strategies like site coordinator calls during visits are suggested for ensur",
      "lexicon_source": "inline_definition",
      "lexicon_ids": null
    },
    {
      "short_form": "EAMG",
      "long_form": "experimental models of autoimmune myasthenia gravis",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 2,
      "context_text": "ti-AChR antibody-positive gMG is provided by histopathological findings of complement deposition and MAC formation at motor end plates, studies demonstrating interference of AChR autoantibodies with functional domains of the AChR (Li, 2025) and NMJ destruction in the presence of MACs (Engel, 1977), experimental models of autoimmune myasthenia gravis (EAMG) (Tiiziin, 2013), and the established clinical benefits achieved by terminal complement inhibition.",
      "lexicon_source": "inline_definition",
      "lexicon_ids": null
    },
    {
      "short_form": "OMG",
      "long_form": "ocular myasthenia gravis",
      "confidence": 0.8,
      "field_type": "DEFINITION_PAIR",
      "page": 1,
      "context_text": "A study to investigate safety and efficacy of gefurulimab compared with placebo in participants aged > 18 years of age with OMG",
      "lexicon_source": "meta-inventory",
      "lexicon_ids": null
    },
    {
      "short_form": "FPI",
      "long_form": "First Patient In",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 1,
      "context_text": "FPI: April 2026",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "AChR",
      "long_form": "acetylcholine receptor",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 2,
      "context_text": "Motor nerves ending at the NMJ release acetylcholine to activate postsynaptic AChRs present on the surface of muscle fibers and induce voluntary muscle contractions. Autoantibodies against the AChR play an essential role in the pathophysiology of MG and may interfere with receptor function or prompt receptor internalization and degradation. Most importantly, though, anti-AChR autoantibodies cause NMJ degeneration through activation of the complement system.",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "NMJ",
      "long_form": "neuromuscular junction",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 2,
      "context_text": "Motor nerves ending at the NMJ release acetylcholine to activate postsynaptic AChRs present on the surface of muscle fibers and induce voluntary muscle contractions. Autoantibodies against the AChR play an essential role in the pathophysiology of MG and may interfere with receptor function or prompt receptor internalization and",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "AChRs",
      "long_form": "acetylcholine receptors",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 2,
      "context_text": "Motor nerves ending at the NMJ release acetylcholine to activate postsynaptic AChRs present on the surface of muscle fibers and induce voluntary muscle contractions. Autoantibodies against the AChR play an essential role in the pathophysiology of MG and may interfere with receptor function or prompt receptor internalization and degradation. Most importantly, though, anti-AChR auto",
      "lexicon_source": "meta-inventory",
      "lexicon_ids": null
    },
    {
      "short_form": "C5",
      "long_form": "Complement Component 5",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 2,
      "context_text": "Anti-AChR autoantibodies are immunoglobulins of the G1 and G3 subtypes which attract complement component Clq. Deposition of Clq triggers the classical complement pathway leading to the cleavage of C5 into C5a and C5b. C5b initiates the assembly of the MACs and destruction of the motor end plate (Dalakas, 2020; Gavriilaki, 2020), reducing the efficiency and reliability of neuromuscular signalling.",
      "lexicon_source": null,
      "lexicon_ids": null
    },
    {
      "short_form": "C5b",
      "long_form": "Complement Component 5B",
      "confidence": 0.8,
      "field_type": "DEFINITION_PAIR",
      "page": 2,
      "context_text": "Anti-AChR autoantibodies are immunoglobulins of the G1 and G3 subtypes which attract complement component Clq. Deposition of Clq triggers the classical complement pathway leading to the cleavage of C5 into C5a and C5b. C5b initiates the assembly of the MACs and destruction of the motor end plate (Dalakas, 2020; Gavriilaki, 2020), reducing the efficiency and reliability of neuromuscular signalling.",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "gMG",
      "long_form": "generalized myasthenia gravis",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 2,
      "context_text": "Evidence of complement activity in anti-AChR antibody-positive gMG is provided by histopathological findings of complement deposition and MAC formation at motor end plates, studies demonstrating interference of AChR autoantibodies with functional domains of the AChR (Li, 2025) and NMJ destruction in the presence of MACs (Engel, 1977), experimental models of autoim",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "MAC",
      "long_form": "Membrane Attack Complex",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 2,
      "context_text": "Evidence of complement activity in anti-AChR antibody-positive gMG is provided by histopathological findings of complement deposition and MAC formation at motor end plates, studies demonstrating interference of AChR autoantibodies with functional domains of the AChR (Li, 2025) and NMJ destruction in the presence of MACs (Engel, 1977), experimental models of autoimmune myasthenia gravis (EAMG) (Tiiziin, 2013), and the established clinical",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "QIW",
      "long_form": "four times a week",
      "confidence": 0.8,
      "field_type": "DEFINITION_PAIR",
      "page": 3,
      "context_text": "Compared with conventional antibodies, gefurulimab has a low molecular weight, allowing it to be concentrated in small volumes suitable for home SC injection convenient for the oMG patients. Another benefit of gefurulimab is its long elimination half-life, allowing convenient QIW dosing intervals. The purpose of this study is to evaluate the safety and efficacy of gefurulimab for the treatment of oMG in adults > 18 years of age with autoantibodies against AChR (AChR+). The study will also evaluate the safety and performance of the administration device (PFS-SD).",
      "lexicon_source": "meta-inventory",
      "lexicon_ids": null
    },
    {
      "short_form": "AChE",
      "long_form": "acetylcholinesterase",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 3,
      "context_text": "herapies for MG aim to improve neuromuscular transmission at the NMJ (symptomatic treatment) or target immunological mechanisms underlying the disease pathophysiology. For patients with MGFA Class 1, or oMG, the standard of care has been unchanged for decades and includes symptomatic treatment with AChE inhibitors, disease-modifying treatment with steroids, steroid-sparing immunosuppressants. None of the standard chronic or maintenance treatment options specifically address the autoimmune defect in MG or the underlying pathophysiology or mechanism of NMJ injury due to anti-AChR antibody-AChR inter",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "ADL",
      "long_form": "Activities of daily living",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 4,
      "context_text": "assess the efficacy of gefurulimab compared with placebo in the treatment o oMG based on change in MGII (PRO + E) ocular score Change from Baseline in the MGII (PRO + E) ocular score at Week 12 To assess the efficacy of gefurulimab compared with placebo in the treatment o oMG based on change in MG-ADL ocular subcomponent score Change from Baseline in the MG-ADL ocular subcomponent score at Week 12 To assess the efficacy of gefurulimab Change from Baseline in the MGII total score (ocular + compared with placebo in the treatment o generalized) at Week 12 oMG based on change in MGII total score To",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "PD",
      "long_form": "Pharmacodynamics",
      "confidence": 0.8,
      "field_type": "DEFINITION_PAIR",
      "page": 5,
      "context_text": "Objectives Endpoints PK/PD: To characterize the PK/PD of gefurulimab in participants with OMG e Serum gefurulimab concentrations e Absolute values, change from Baseline, and percent change from Baseline in serum free and total C5 concentrations Immunogenicity: To assess the immunogenicity to gefurulimab in participants with",
      "lexicon_source": "trial_acronyms_lexicon.json",
      "lexicon_ids": [
        {
          "source": "ClinicalTrials.gov",
          "id": "NCT06888869"
        }
      ]
    },
    {
      "short_form": "TBC",
      "long_form": "To be continued",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 5,
      "context_text": "the safety and tolerability of gefurulimab compared to placebo and the long-term safety and tolerability of gefurulimab in participants with OMG e Incidence and severity of AEs and SAEs e Clinically relevant changes from Baseline in vital signs, ECGs, and laboratory parameters Tertiary/Exploratory: TBC e Digital endpoint e To evaluate the safety and performance of the administration device (PFS-SD) TBC e Potential digital endpoints to explore: — Digital interpretation of facial recognition recording — Saccadic/eye tracking function e Device User Experience Questionnaire * Does not represent a com",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "SAEs",
      "long_form": "serious adverse events",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 5,
      "context_text": "pants with oMG ADA incidence, response categories, and titer over time for the duration of the study Safety: To assess the safety and tolerability of gefurulimab compared to placebo and the long-term safety and tolerability of gefurulimab in participants with OMG e Incidence and severity of AEs and SAEs e Clinically relevant changes from Baseline in vital signs, ECGs, and laboratory parameters Tertiary/Exploratory: TBC e Digital endpoint e To evaluate the safety and performance of the administration device (PFS-SD) TBC e Potential digital endpoints to explore: — Digital interpretation of facial re",
      "lexicon_source": "meta-inventory",
      "lexicon_ids": null
    },
    {
      "short_form": "RCT",
      "long_form": "randomised controlled trial",
      "confidence": 0.95,
      "field_type": "DEFINITION_PAIR",
      "page": 6,
      "context_text": "A non-binding interim analysis for efficacy and futility will be performed when approximately 96 participants have completed Week 12 of the RCT Period. The futility will be assessed using the predictive probability of final study success.",
      "lexicon_source": null,
      "lexicon_ids": null
    },
    {
      "short_form": "OLE",
      "long_form": "open-label extension",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 6,
      "context_text": "The study will consist of 3 periods: Screening (< 4 weeks), RCT (12 weeks), and OLE (52 weeks) (Figure 1). Consenting participants will be screened for study eligibility up to 4 weeks prior to Day 1. Participants with confirmed oMG (MGFA Class I) (Jaretzki, 2000) and a positive serological test for AChR autoantibodies at Screening will be included if their MGII (PRO) ocular score",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "EOS",
      "long_form": "End Of Study",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 7,
      "context_text": "If a participant discontinues treatment or withdraws from the study early or completes the study prior to the end of the OLE Period, the participant will be encouraged to return for an ET/EOS Visit as soon as possible.",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "EOM",
      "long_form": "extraocular muscles (movements)",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 7,
      "context_text": "The goal of this study is to assess the efficacy and safety of gefurulimab compared with placebo in the treatment of adults with oMG based on the ability of participants to perform activities of daily living, and improvement in participants’ symptoms of ptosis and/or diplopia due to improved EOM strength. Primary and key secondary objectives reflect this goal:",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "exam",
      "long_form": "examination",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 7,
      "context_text": "e The MGII is a patient centered composite score measuring MG impairment and severity and is responsive to change in status. The ocular subscore (8 items, ranging from 0-23) consists of 6 PRO items with a maximum score of 18 and 2 physical exam items with a maximum score of 5. MGII PRO ocular score as primary endpoint and and PRO + E ocular score as secondary endpoint will be used to assess the impact of oMG and measure treatment-associated changes in disease severity.",
      "lexicon_source": "meta-inventory",
      "lexicon_ids": null
    },
    {
      "short_form": "TBD",
      "long_form": "To be decided",
      "confidence": 0.8,
      "field_type": "DEFINITION_PAIR",
      "page": 8,
      "context_text": "A fixed dose regimen is being proposed based on modeling and dosing simulations using clinical PK, PD and ADA data from a first-in-human Phase | study of gefurulimab (Study ALXN1720-HV-101), TBD and subject to change based on PREVAIL study data.",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "PE",
      "long_form": "plasma exchange",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 8,
      "context_text": "A supplemental dose of 300 mg of TRADENAME should be administered after every other PE or PP session (within 4 hours, if possible). If PE or PP occurs on a regularly scheduled dosing day, the maintenance dose (and the supplemental dose, if applicable) must be administered after completion of the PE or PP session (within 4 hours, if possible).",
      "lexicon_source": "meta-inventory",
      "lexicon_ids": null
    },
    {
      "short_form": "CSP",
      "long_form": "Clinical Study Protocol",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 9,
      "context_text": "Inclusion and exclusion criteria are provided below. Note these are not inclusive of entire list from CSP template, which will be included at time of protocol development",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "MRI",
      "long_form": "magnetic resonance imaging",
      "confidence": 0.8,
      "field_type": "DEFINITION_PAIR",
      "page": 10,
      "context_text": "e Historical MRI within past 12 months without fatty replacement in EOM or",
      "lexicon_source": null,
      "lexicon_ids": null
    },
    {
      "short_form": "IVIG",
      "long_form": "immunoglobulins, intravenous",
      "confidence": 0.8,
      "field_type": "DEFINITION_PAIR",
      "page": 10,
      "context_text": "e Demonstrated response (ie, improvement in at least 1 oMG sign, based on investigator judgment) to treatment (IVIg, PP/PE [ie, including plasmapheresis in addition to plasma exchange [PLEX]]), pyridostigmine, and/or steroids) in the past year",
      "lexicon_source": "2025_08_umls_biological_abbreviations_v5.tsv",
      "lexicon_ids": [
        {
          "source": "UMLS:MTH",
          "id": "IVIG"
        }
      ]
    },
    {
      "short_form": "MuSK",
      "long_form": "Muscle-Specific Kinase",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 12,
      "context_text": "e Historical anti MuSK or anti LRP-4 Ab + status",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "ALT",
      "long_form": "alanine aminotransferase",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 12,
      "context_text": "— ALT>2 x the ULN",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "ULN",
      "long_form": "upper limit of normal",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 12,
      "context_text": "— ALT>2 x the ULN",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "HIV",
      "long_form": "human immunodeficiency virus",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 12,
      "context_text": "e Positive HIV antibody test or a positive serological test for HIV-1 or HIV-2.",
      "lexicon_source": null,
      "lexicon_ids": null
    },
    {
      "short_form": "Hbsag",
      "long_form": "HEPATITIS B VIRUS HBSAG SURFACE PROTEIN ANTIGEN",
      "confidence": 0.8,
      "field_type": "DEFINITION_PAIR",
      "page": 13,
      "context_text": "e Evidence of hepatitis B or hepatitis C viral infection or presence of HBsAg or HBcAb with negative surface antibody (anti-HBs), or HCV infection (HCV antibody positive, expect for participants with document successful treatment). If locally available, SVR should be documented or established at Screening.",
      "lexicon_source": "2025_chembl_drugs.json",
      "lexicon_ids": [
        {
          "source": "ChEMBL",
          "id": "CHEMBL4297973"
        }
      ]
    },
    {
      "short_form": "HCV",
      "long_form": "Hepatitis C Virus",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 13,
      "context_text": "e Evidence of hepatitis B or hepatitis C viral infection or presence of HBsAg or HBcAb with negative surface antibody (anti-HBs), or HCV infection (HCV antibody positive, expect for participants with document successful treatment). If locally available, SVR should be documented or established at Screening.",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "SVR",
      "long_form": "sustained virological response",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 13,
      "context_text": "e Evidence of hepatitis B or hepatitis C viral infection or presence of HBsAg or HBcAb with negative surface antibody (anti-HBs), or HCV infection (HCV antibody positive, expect for participants with document successful treatment). If locally available, SVR should be documented or established at Screening.",
      "lexicon_source": "meta-inventory",
      "lexicon_ids": null
    },
    {
      "short_form": "AxMP",
      "long_form": "Auxiliary Medicinal Product",
      "confidence": 0.8,
      "field_type": "DEFINITION_PAIR",
      "page": 14,
      "context_text": "ns as (TBD and Subject Q1W MD (starting Day 8) gefurulimab to change) during the RCT Period. during the RCT Period. For dosing during the OLE Period, | For dosing during the OLE Period, see see Section 4.3 Section 4.3 Route of SC injection SC injection Administration Use Experimental Placebo IMP or AxMP IMP IMP Sourcing Provided centrally by Alexion Provided centrally by Alexion Packaging and Gefurulimab will be provided ina _ | Placebo will be provided in a PFS-SD. Labeling PFS-SD. One kit contains 1 PFS- | One kit contains 1 PFS-SD. Kits will be SD. Kits will be labeled as labeled as required pe",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "pH",
      "long_form": "potential of hydrogen",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 14,
      "context_text": "Group Name Treatment 1 Treatment 2 Intervention Name ALXN1720-PFS-SD Placebo-PFS-SD Type Integral medicinal product: biological product and device Integral medicinal product: placebo formulation and device Dose Formulation Sterile liquid gefurulimab is formulated at pH 6.7 and each syringe contains 300 mg of gefurulimab in 20 mM L-histidine/histidine hydrochloride, 100 mM glycine, 200 mM sucrose, 0.08% (w/v) polysorbate 80 Device configuration/style/model: BD 2.25mL Neopak™ Prefilled Syringe with Ultrasafe Plus™ Passive Needle Safety Device Sterile liquid gefurul",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "RTSM",
      "long_form": "Randomization And Trial Supply Management",
      "confidence": 0.8,
      "field_type": "DEFINITION_PAIR",
      "page": 14,
      "context_text": "igator has verified the eligibility criteria. Participants will be stratified by geographical region (eg, North America, Europe), steroid use at baseline (Yes or No) and baseline MGII (PRO) ocular score category (6 to 10, or 11 to 18) and randomized 1:1 to gefurulimab or placebo using a centralized RTSM.",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "IRT",
      "long_form": "Interactive Response Technology",
      "confidence": 0.85,
      "field_type": "DEFINITION_PAIR",
      "page": 15,
      "context_text": "cretion, contact Alexion to discuss the situation prior to unmasking a participant’s intervention assignment unless this could delay emergency treatment for the participant. If unmasking is deemed necessary, the Investigator will be able to unmask the participant’s intervention assignment using the IRT. Ifa participant’s intervention assignment is unmasked, Alexion must be notified within 24 hours after breaking the masking.",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "SUSAR",
      "long_form": "Suspected Unexpected Serious Adverse Reaction",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 15,
      "context_text": "In the event of a SUSAR reporting guidance in protocol must be followed. The mask will be maintained for persons responsible for the ongoing conduct of the study (eg, Monitors, Investigators) and those responsible for data analysis and interpretation of results.",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "DMC",
      "long_form": "Data Monitoring Committee",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 15,
      "context_text": "To manage the uncertainty associated with the assumed treatment effect for the primary endpoint, an interim analysis for sample size re-estimation will be performed after approximately 56 participants have completed Week 12 of the RCT Period. The analysis will be reviewed by an independent DMC. The sample size may be increased to a maximum of 186 participants if the conditional power based on the estimated treatment effect in the primary endpoint falls within",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "SAP",
      "long_form": "Stat Anal Plan",
      "confidence": 0.85,
      "field_type": "DEFINITION_PAIR",
      "page": 16,
      "context_text": "the promising zone of 41% to 90%. Additional details of the interim analysis will be provided in the SAP.",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "FAS",
      "long_form": "Full Analysis Set",
      "confidence": 0.95,
      "field_type": "DEFINITION_PAIR",
      "page": 16,
      "context_text": "The Full Analysis Set (FAS) will be the primary population used for the analysis of all efficacy endpoints for the RCT Period. Supplemental per protocol analyses for primary and secondary efficacy endpoints will be performed based on the Per Protocol Set (PPS) in the same manner as done for the FAS. Safety analyses will be p",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "SS",
      "long_form": "Safety Set",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 16,
      "context_text": "tion used for the analysis of all efficacy endpoints for the RCT Period. Supplemental per protocol analyses for primary and secondary efficacy endpoints will be performed based on the Per Protocol Set (PPS) in the same manner as done for the FAS. Safety analyses will be performed on the Safety Set (SS).",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "MMRM",
      "long_form": "Mixed Effect Model For Repeated Measures",
      "confidence": 0.8,
      "field_type": "DEFINITION_PAIR",
      "page": 16,
      "context_text": "e The MMRM method is used to compare gefurulimab and placebo in the change from Baseline of MGII (PRO) ocular score at Week 12;",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "IAS",
      "long_form": "Immunogenicity Analysis Set",
      "confidence": 0.85,
      "field_type": "DEFINITION_PAIR",
      "page": 17,
      "context_text": "aseline PD data point. Safety Set (SS) All randomized participants who receive at least 1 dose of study ntervention. Participants will be analyzed according to the study ntervention they received. Immunogenicity Analysis All randomized participants who receive at least 1 dose (full or partial) Set (IAS) of study intervention and have at least 1 reportable postdose result in the ADA assay. Participants will be analyzed according to the study ntervention they received. OLE Set All randomized participants who received at least 1 dose of gefurulimab in the OLE period. Gefurulimab Treated Set All part",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "SoA",
      "long_form": "Standard of Care",
      "confidence": 0.8,
      "field_type": "DEFINITION_PAIR",
      "page": 18,
      "context_text": "Blood samples will be collected for the determination of serum gefurulimab, free C5 and total C5 concentrations at the timepoints specified in the SoA. Individual serum concentrations for all participants who receive at least 1 dose of gefurulimab and who have evaluable PK/PD data will be used to summarize PK/PD parameters for gefurulimab. Descriptive statistics will be presented for all PK/PD endpoints at each sampling time. The PD effects of ge",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "NAb",
      "long_form": "neutralising antibody",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 18,
      "context_text": "Immunogenicity variables include ADA status, ADA response category, and ADA incidence, ADA titer and NAb incidence over the duration of the study.",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "ECG",
      "long_form": "Electrocardiography",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 18,
      "context_text": "The safety and tolerability of gefurulimab will be assessed based on AEs and findings in clinical laboratory tests, ECG, and vital signs. Safety analyses will be performed on the SS and OLE Set based on the study period under consideration.",
      "lexicon_source": "2025_08_umls_clinical_abbreviations_v5.tsv",
      "lexicon_ids": [
        {
          "source": "UMLS:MTH",
          "id": "ECG"
        }
      ]
    },
    {
      "short_form": "FSH",
      "long_form": "Follicle Stimulating Hormone",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 21,
      "context_text": "ks-4W to wi | W2 | W3 | W4 | W5 | W6 | W7 ws wo | wi0 |} Wil wi2 D-1 Visit Type Cc Cc Cc Cc R Cc R Cc R Cc R R R Cc Cc Cc C = Clinic Visit R = Remote Visit Height XxX Demographics x N meningitidis x vaccination Dispense patient safety XxX card Serum pregnancy test x x x Urine pregnancy test x x x x FSH XxX HIV testing XxX Hepatitis B testing XxX Hepatitis C testing! XxX IVIGg testing XxX Clinical laboratory XxX XxX XxX XxX XxX XxX tests Randomization XxX",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "QoL",
      "long_form": "Quality Of Life",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 22,
      "context_text": "isit Type Cc Cc Cc Cc R Cc R Cc R Cc R R R Cc Cc Cc C = Clinic Visit R = Remote Visit Efficacy MGII (PRO) xX xX xX xX xX xX xX xX xX xX xX MGII (Exam) xX xX xX xX xX xX xX xX MG-ADL xX xX xX xX xX xX xX xX xX xX x xX x xX xX xX NEI-VFQ-25 xX xX xX xX xX xX xX xX MG-QoL15r xX xX xX xX xX xX xX Neuro-QoL fatigue XxX Xx XxX XxX XxX XxX (short form) SF-36° xX xX xX xX xX xX PGI-S (ocular) xX xX xX xX xX xX xX xX xX xX xX PGI-C (ocular) xX xX xX xX xX xX MGFA-PIS xX xX Digital biomarkers-TBD Safety",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "AE",
      "long_form": "Adverse Event",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 30,
      "context_text": "e AE that would, in the opinion of the Investigator, make continued participation in the study an unacceptable risk",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "eCRF",
      "long_form": "Electronic Case Report Form",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 30,
      "context_text": "The reason for treatment discontinuation will be recorded in the eCRF. If study intervention is discontinued because of a participant’s pregnancy, the Investigator will make a reasonable attempt to follow up, in accordance with local laws and regulations, until the outcome of the pregnancy is known.",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "SAE",
      "long_form": "Serious Adverse Event",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 33,
      "context_text": "— Laboratory assessments performed at the institution’s local laboratory or central laboratory that require a change in participant management or are considered clinically significant by the Investigator must be recorded in the AE or SAE form. When possible, values outside of the reference range should be entered, eg, in a free text field.",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "HBc",
      "long_form": "hepatitis B core antigen",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 33,
      "context_text": "Similarly, participants who are positive for HBsAg, positive anti-HBc with negative anti-HBs, or HCV antibodies will not be randomized unless successful treatment and, if locally available, SVR are documented.",
      "lexicon_source": "meta-inventory",
      "lexicon_ids": null
    },
    {
      "short_form": "HRT",
      "long_form": "Hormonal Replacement Therapy",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 33,
      "context_text": "FSH may be obtained to confirm postmenopausal status in female participants who are considered postmenopausal. A high FSH level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or HRT.",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "IgG",
      "long_form": "Immunoglobulin G",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 35,
      "context_text": "Abbreviation or | Explanation Term HBsAg hepatitis B surface antigen HCV hepatitis C virus Hib Haemophilus influenzae type b HIV human immunodeficiency virus HRT hormone replacement therapy IAS immunogenicity analysis set IE intercurrent event IEC Independent Ethics Committee IgG immunoglobulin G IMP investigational medicinal product IRB Institutional Review Board IRT interactive response technology ISC independent statistical center IVIg intravenous immunoglobulin LD loading dose LRP-4 low-density lipoprotein receptor related protein 4 MAC membrane attack complex MD mainte",
      "lexicon_source": null,
      "lexicon_ids": null
    },
    {
      "short_form": "PCS",
      "long_form": "Painful Channelopathies Study",
      "confidence": 0.7,
      "field_type": "DEFINITION_PAIR",
      "page": 40,
      "context_text": "Risk Category Risk Description Risk Response (Accept/Mitigate) Discuss at rDRC (Yes/No) Participant population Risk 1: Adolescent Challenges: Risk 1: Mitigate — Following the CDRC discussion the study will | No Differential PK/PD, adherence issues, | now be recruiting only adults -PCS is revised to reflect this and consent complexities in patients change (note added on Sept 17, 2025) aged 12-17. (Mitigations prior to the CRDC meeting: Implement frequent monitoring for adherence via patient diaries and reminders; Develop age-specific consent/assent training and materials to ensur",
      "lexicon_source": "trial_acronyms_lexicon.json",
      "lexicon_ids": [
        {
          "source": "ClinicalTrials.gov",
          "id": "NCT02696746"
        }
      ]
    },
    {
      "short_form": "PROs",
      "long_form": "Patient-reported outcomes",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 40,
      "context_text": "92025: Diplopia or Ptosis will not compromise consent comprehension or PRO completion because we are able to consent people who are severely visually compromised. Consents are just read out to them by someone else and then we ask for comprehension. Consent would be read out to people who need help. PROs could be completed by asking them over the phone for remote visits. If they have ptosis, it's painful when you are lifting one eyelid. In case anybody has severe ptosis, we can always ask the questions and then the administrator can note down the responses. Risk 3: Diagnostic Misclassification: Ris",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "MGI",
      "long_form": "modified gingival index",
      "confidence": 0.8,
      "field_type": "DEFINITION_PAIR",
      "page": 45,
      "context_text": "r the same assessment, the assessment may be invalid. Train and certify raters. Train patients and caregivers on PRO tool use to ensure accurate reporting over the recall period. Discussion: It was noted that while the symptoms are subjective to the patient, the Patient-Reported Outcome (PRO) tool (MGI) used as the primary outcome measure captures data over a 7-14 days recall period, reducing variability. It was clarified that variability is inherent to myasthenia gravis (MG), not specifically ocular symptoms, suggesting a reframing of the risk to \"variable symptoms in ocular MG.\" PRO tool is val",
      "lexicon_source": "meta-inventory",
      "lexicon_ids": null
    },
    {
      "short_form": "CRO",
      "long_form": "Contract research organization",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 48,
      "context_text": "Risk Category Risk Description Risk Response (Accept/Mitigate) Discuss at rDRC (Yes/No) Complexity RISK 1: Incomplete Data Transfer: Immunogenicity samples marked \"pending analysis\" at database lock due to CRO transfer delays. RISK 2: Participant Burden: Frequent visits or complex procedures increasing dropout, especially in adolescents Risk 1: Mitigate Connect with Prevail DM and oMG DM on monitoring processes and periodic checks during mock data transfers. DM input for effective monitoring strategies,",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "HCP",
      "long_form": "Health care provider",
      "confidence": 0.9,
      "field_type": "DEFINITION_PAIR",
      "page": 49,
      "context_text": "PROs like MGI and MG-ADL in Prevail were administered by site staff over the phone, not independently by patients at home, ensuring control. RISK 2: Viscosity differences pose a_ | Risk 2: Mitigate risk during the RCT to OLE transition | The dose at the transition from RCT to OLE is administered by HCP (Week 12) Discussion: Patients remained blinded during RCT. Viscosity differences pose a risk during the RCT to OLE transition where patients may receive mixed active and placebo syringes. It was explained that Healthcare Professionals (HCPs) administer these doses to prevent patients from feeling",
      "lexicon_source": "2025_08_abbreviation_general.json",
      "lexicon_ids": null
    },
    {
      "short_form": "SAS",
      "long_form": "Statistical Analysis System",
      "confidence": 0.85,
      "field_type": "DEFINITION_PAIR",
      "page": 1,
      "context_text": " the first dose of study intervention unless stated otherwise. Analyses will be performed using the SAS software Version 9.4 or higher. 7.1. Sample Size Determination The sample size determination of N =",
      "lexicon_source": "orchestrator:direct_search",
      "lexicon_ids": null
    },
    {
      "short_form": "G1",
      "long_form": null,
      "confidence": 0.75,
      "field_type": "SHORT_FORM_ONLY",
      "page": 1,
      "context_text": "on through activation of the complement system. Anti-AChR autoantibodies are immunoglobulins of the G1 and G3 subtypes which attract complement component Clq. Deposition of Clq triggers the classical co",
      "lexicon_source": "orchestrator:llm_extraction",
      "lexicon_ids": null
    },
    {
      "short_form": "G3",
      "long_form": null,
      "confidence": 0.75,
      "field_type": "SHORT_FORM_ONLY",
      "page": 1,
      "context_text": "ugh activation of the complement system. Anti-AChR autoantibodies are immunoglobulins of the G1 and G3 subtypes which attract complement component Clq. Deposition of Clq triggers the classical complemen",
      "lexicon_source": "orchestrator:llm_extraction",
      "lexicon_ids": null
    },
    {
      "short_form": "C5a",
      "long_form": null,
      "confidence": 0.75,
      "field_type": "SHORT_FORM_ONLY",
      "page": 1,
      "context_text": "Clq. Deposition of Clq triggers the classical complement pathway leading to the cleavage of C5 into C5a and C5b. C5b initiates the assembly of the MACs and destruction of the motor end plate (Dalakas, 20",
      "lexicon_source": "orchestrator:llm_extraction",
      "lexicon_ids": null
    },
    {
      "short_form": "MACs",
      "long_form": null,
      "confidence": 0.75,
      "field_type": "SHORT_FORM_ONLY",
      "page": 1,
      "context_text": "omplement pathway leading to the cleavage of C5 into C5a and C5b. C5b initiates the assembly of the MACs and destruction of the motor end plate (Dalakas, 2020; Gavriilaki, 2020), reducing the efficiency a",
      "lexicon_source": "orchestrator:llm_extraction",
      "lexicon_ids": null
    },
    {
      "short_form": "PREVAIL",
      "long_form": null,
      "confidence": 0.75,
      "field_type": "SHORT_FORM_ONLY",
      "page": 1,
      "context_text": " by neuromuscular disease experts in treatment guidelines (Narayanaswami, 2021; Sanders, 2016). The PREVAIL Phase 3 gefurulimab study in gMG showed that gefurulimab met the primary and all secondary endpoint",
      "lexicon_source": "orchestrator:llm_extraction",
      "lexicon_ids": null
    },
    {
      "short_form": "EOMs",
      "long_form": null,
      "confidence": 0.75,
      "field_type": "SHORT_FORM_ONLY",
      "page": 1,
      "context_text": "tor loss for a variety of reasons including higher frequency of synaptic firing in twitch fibers of EOMs compared to limb muscles, making them more susceptible to fatigue; fewer AChRs on tonic muscles nec",
      "lexicon_source": "orchestrator:llm_extraction",
      "lexicon_ids": null
    },
    {
      "short_form": "SoC",
      "long_form": "Standard of Care",
      "confidence": 0.75,
      "field_type": "SHORT_FORM_ONLY",
      "page": 1,
      "context_text": "ril, 2024; Soltys, 2008). A proportion of oMG patients do not achieve adequate control with current SoC treatment (Behbehani, 2023; Kerty, 2014), resulting in chronic and fluctuating diplopia and ptosis.",
      "lexicon_source": "orchestrator:llm_extraction",
      "lexicon_ids": null
    },
    {
      "short_form": "PFS-SD",
      "long_form": null,
      "confidence": 0.75,
      "field_type": "SHORT_FORM_ONLY",
      "page": 1,
      "context_text": "AChR (AChR+). The study will also evaluate the safety and performance of the administration device (PFS-SD). Current therapies for MG aim to improve neuromuscular transmission at the NMJ (symptomatic treatm",
      "lexicon_source": "orchestrator:llm_extraction",
      "lexicon_ids": null
    },
    {
      "short_form": "Ab",
      "long_form": null,
      "confidence": 0.75,
      "field_type": "SHORT_FORM_ONLY",
      "page": 1,
      "context_text": "dy will compare gefurulimab with placebo in participants > 18 years of age (at Screening) with AChR Ab + oMG. The estimand corresponding to the primary objective is defined as follows: e Population: Adu",
      "lexicon_source": "orchestrator:llm_extraction",
      "lexicon_ids": null
    },
    {
      "short_form": "IEs",
      "long_form": null,
      "confidence": 0.75,
      "field_type": "SHORT_FORM_ONLY",
      "page": 1,
      "context_text": " Adults with AChR Ab+ oMG e Treatments: gefurulimab vs placebo e Intercurrent events: The following IEs will be handled using a treatment-policy strategy, ie, all data collected will be included in the a",
      "lexicon_source": "orchestrator:llm_extraction",
      "lexicon_ids": null
    },
    {
      "short_form": "ADA",
      "long_form": null,
      "confidence": 0.75,
      "field_type": "SHORT_FORM_ONLY",
      "page": 1,
      "context_text": "concentrations Immunogenicity: To assess the immunogenicity to gefurulimab in participants with oMG ADA incidence, response categories, and titer over time for the duration of the study Safety: To assess",
      "lexicon_source": "orchestrator:llm_extraction",
      "lexicon_ids": null
    },
    {
      "short_form": "PFS",
      "long_form": null,
      "confidence": 0.75,
      "field_type": "SHORT_FORM_ONLY",
      "page": 1,
      "context_text": "AChR (AChR+). The study will also evaluate the safety and performance of the administration device (PFS-SD). Current therapies for MG aim to improve neuromuscular transmission at the NMJ (symptomatic tre",
      "lexicon_source": "orchestrator:llm_extraction",
      "lexicon_ids": null
    },
    {
      "short_form": "SD",
      "long_form": null,
      "confidence": 0.75,
      "field_type": "SHORT_FORM_ONLY",
      "page": 1,
      "context_text": " (AChR+). The study will also evaluate the safety and performance of the administration device (PFS-SD). Current therapies for MG aim to improve neuromuscular transmission at the NMJ (symptomatic treatm",
      "lexicon_source": "orchestrator:llm_extraction",
      "lexicon_ids": null
    }
  ],
  "diseases": [
    {
      "name": "46,XX testicular difference of sex development",
      "matched_text": "xX",
      "abbreviation": "XX",
      "confidence": 0.95,
      "is_rare": true,
      "icd10": "Q99.1",
      "orpha": "ORPHA:393"
    },
    {
      "name": "Spontaneous intestinal perforation",
      "matched_text": "SIP",
      "abbreviation": "SIP",
      "confidence": 0.95,
      "is_rare": true,
      "icd10": "K63.1",
      "orpha": "ORPHA:645793"
    },
    {
      "name": "Well-differentiated liposarcoma",
      "matched_text": "ALT",
      "abbreviation": "ALT",
      "confidence": 0.6,
      "is_rare": true,
      "icd10": "C49.9",
      "orpha": "ORPHA:99971"
    },
    {
      "name": "Infantile dystonia-parkinsonism",
      "matched_text": "IPD",
      "abbreviation": "IPD",
      "confidence": 0.95,
      "is_rare": true,
      "icd10": "G24.8",
      "orpha": "ORPHA:238455"
    },
    {
      "name": "inflammatory bowel disease",
      "matched_text": "inflammatory bowel disease",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": null
    },
    {
      "name": "Shwachman-Diamond syndrome",
      "matched_text": "SDs",
      "abbreviation": "SDS",
      "confidence": 0.95,
      "is_rare": true,
      "icd10": "D61.0",
      "orpha": "ORPHA:811"
    },
    {
      "name": "fungal infectious disease",
      "matched_text": "fungal infection",
      "abbreviation": null,
      "confidence": 0.85,
      "is_rare": false,
      "icd10": "ICD10CM:B35-B49",
      "orpha": null
    },
    {
      "name": "hereditary coproporphyria",
      "matched_text": "HCP",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": "Orphanet:79273"
    },
    {
      "name": "Ocular myasthenia gravis",
      "matched_text": "OMG",
      "abbreviation": "OMG",
      "confidence": 0.95,
      "is_rare": true,
      "icd10": "G70.0",
      "orpha": "ORPHA:589"
    },
    {
      "name": "viral infectious disease",
      "matched_text": "viral infection",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": null
    },
    {
      "name": "meningococcal infection",
      "matched_text": "meningococcal infection",
      "abbreviation": null,
      "confidence": 0.85,
      "is_rare": false,
      "icd10": "ICD10CM:A39",
      "orpha": null
    },
    {
      "name": "Kapur-Toriello syndrome",
      "matched_text": "Eye",
      "abbreviation": null,
      "confidence": 0.6,
      "is_rare": true,
      "icd10": null,
      "orpha": "ORPHA:2328"
    },
    {
      "name": "Middle aortic syndrome",
      "matched_text": "MAC",
      "abbreviation": "MAC",
      "confidence": 0.95,
      "is_rare": true,
      "icd10": "Q25.1",
      "orpha": "ORPHA:1456"
    },
    {
      "name": "Pulmonary hypertension",
      "matched_text": "pH",
      "abbreviation": "PH",
      "confidence": 1.0,
      "is_rare": false,
      "icd10": "I27.0",
      "orpha": "ORPHA:182090"
    },
    {
      "name": "Fetal alcohol syndrome",
      "matched_text": "FAS",
      "abbreviation": "FAS",
      "confidence": 0.6,
      "is_rare": true,
      "icd10": "Q86.0",
      "orpha": "ORPHA:1915"
    },
    {
      "name": "Epithelioid hemangioma",
      "matched_text": "EH",
      "abbreviation": "EH",
      "confidence": 0.6,
      "is_rare": true,
      "icd10": null,
      "orpha": "ORPHA:675396"
    },
    {
      "name": "episodic ataxia type 2",
      "matched_text": "CAPA",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": "Orphanet:97"
    },
    {
      "name": "neuromuscular disease",
      "matched_text": "neuromuscular disease",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": "Orphanet:68381"
    },
    {
      "name": "rheumatoid arthritis",
      "matched_text": "rheumatoid arthritis",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": "Orphanet:284130"
    },
    {
      "name": "multiple sclerosis",
      "matched_text": "multiple sclerosis",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": "ICD10CM:G35",
      "orpha": "Orphanet:802"
    },
    {
      "name": "autoimmune disease",
      "matched_text": "autoimmune disease",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": null
    },
    {
      "name": "myasthenia gravis",
      "matched_text": "Myasthenia Gravis",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": "ICD10CM:G70.0",
      "orpha": "Orphanet:589"
    },
    {
      "name": "hypersensitivity",
      "matched_text": "hypersensitivity",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": null
    },
    {
      "name": "immunodeficiency",
      "matched_text": "immunodeficiency",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": null
    },
    {
      "name": "Menkes disease",
      "matched_text": "MD",
      "abbreviation": "MD",
      "confidence": 0.6,
      "is_rare": true,
      "icd10": "E83.0",
      "orpha": "ORPHA:565"
    },
    {
      "name": "serum sickness",
      "matched_text": "serum sickness",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": null
    },
    {
      "name": "bronchospasm",
      "matched_text": "bronchospasm",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": null
    },
    {
      "name": "rare disease",
      "matched_text": "rare disease",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": null
    },
    {
      "name": "Hepatitis B",
      "matched_text": "hepatitis B",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": null
    },
    {
      "name": "hypotension",
      "matched_text": "hypotension",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": "ICD10CM:I95",
      "orpha": null
    },
    {
      "name": "anaphylaxis",
      "matched_text": "anaphylaxis",
      "abbreviation": null,
      "confidence": 0.85,
      "is_rare": false,
      "icd10": null,
      "orpha": null
    },
    {
      "name": "malignancy",
      "matched_text": "malignancy",
      "abbreviation": null,
      "confidence": 0.85,
      "is_rare": false,
      "icd10": null,
      "orpha": null
    },
    {
      "name": "condition",
      "matched_text": "condition",
      "abbreviation": null,
      "confidence": 0.65,
      "is_rare": false,
      "icd10": null,
      "orpha": "Orphanet:377788"
    },
    {
      "name": "infection",
      "matched_text": "infection",
      "abbreviation": null,
      "confidence": 0.85,
      "is_rare": false,
      "icd10": "ICD10CM:A00-B99",
      "orpha": null
    },
    {
      "name": "amblyopia",
      "matched_text": "amblyopia",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": null
    },
    {
      "name": "Hepatitis",
      "matched_text": "hepatitis",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": null
    },
    {
      "name": "acquired",
      "matched_text": "acquired",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": "Orphanet:409941"
    },
    {
      "name": "sterile",
      "matched_text": "Sterile",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": null
    },
    {
      "name": "ptosis",
      "matched_text": "ptosis",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": null
    },
    {
      "name": "asthma",
      "matched_text": "asthma",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": "ICD10CM:J45",
      "orpha": null
    },
    {
      "name": "injury",
      "matched_text": "injury",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": null
    },
    {
      "name": "MACS",
      "matched_text": "MACs",
      "abbreviation": null,
      "confidence": 0.6,
      "is_rare": false,
      "icd10": null,
      "orpha": null
    },
    {
      "name": "PROS",
      "matched_text": "PROs",
      "abbreviation": null,
      "confidence": 0.6,
      "is_rare": false,
      "icd10": null,
      "orpha": "Orphanet:530313"
    },
    {
      "name": "ADA",
      "matched_text": "ADA",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": "Orphanet:277"
    },
    {
      "name": "EOS",
      "matched_text": "EOS",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": "Orphanet:90341"
    },
    {
      "name": "CSP",
      "matched_text": "CSP",
      "abbreviation": null,
      "confidence": 0.6,
      "is_rare": false,
      "icd10": null,
      "orpha": null
    },
    {
      "name": "CIS",
      "matched_text": "CIS",
      "abbreviation": null,
      "confidence": 0.6,
      "is_rare": false,
      "icd10": null,
      "orpha": null
    },
    {
      "name": "DMC",
      "matched_text": "DMC",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": "Orphanet:239"
    },
    {
      "name": "PPS",
      "matched_text": "PPS",
      "abbreviation": null,
      "confidence": 0.6,
      "is_rare": false,
      "icd10": null,
      "orpha": "Orphanet:294963"
    },
    {
      "name": "SAS",
      "matched_text": "SAS",
      "abbreviation": null,
      "confidence": 0.6,
      "is_rare": false,
      "icd10": null,
      "orpha": "Orphanet:576278"
    },
    {
      "name": "LAN",
      "matched_text": "Lan",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": null
    },
    {
      "name": "ENS",
      "matched_text": "ENS",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": null
    },
    {
      "name": "PCS",
      "matched_text": "PCS",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": null
    },
    {
      "name": "MRD",
      "matched_text": "MRD",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare": false,
      "icd10": null,
      "orpha": "Orphanet:97364"
    }
  ],
  "drugs": [
    {
      "name": "gefurulimab",
      "matched_text": "Gefurulimab",
      "compound_id": null,
      "confidence": 0.85,
      "is_investigational": true,
      "phase": null
    },
    {
      "name": "eculizumab",
      "matched_text": "eculizumab",
      "compound_id": null,
      "confidence": 0.85,
      "is_investigational": true,
      "phase": null
    },
    {
      "name": "ravulizumab",
      "matched_text": "ravulizumab",
      "compound_id": null,
      "confidence": 0.85,
      "is_investigational": true,
      "phase": null
    },
    {
      "name": "ALXN1720",
      "matched_text": "ALXN1720",
      "compound_id": "ALXN1720",
      "confidence": 0.8,
      "is_investigational": true,
      "phase": null
    },
    {
      "name": "HV-101",
      "matched_text": "HV-101",
      "compound_id": "HV-101",
      "confidence": 0.8,
      "is_investigational": true,
      "phase": null
    },
    {
      "name": "HV-104",
      "matched_text": "HV-104",
      "compound_id": "HV-104",
      "confidence": 0.8,
      "is_investigational": true,
      "phase": null
    },
    {
      "name": "Steroids",
      "matched_text": "steroids",
      "compound_id": null,
      "confidence": 0.85,
      "is_investigational": true,
      "phase": "NOT_YET_RECRUITING"
    },
    {
      "name": "Cyclophosphamide",
      "matched_text": "cyclophosphamide",
      "compound_id": null,
      "confidence": 0.85,
      "is_investigational": true,
      "phase": "ACTIVE_NOT_RECRUITING"
    },
    {
      "name": "corticosteroids",
      "matched_text": "corticosteroids",
      "compound_id": null,
      "confidence": 0.85,
      "is_investigational": true,
      "phase": "NOT_YET_RECRUITING"
    },
    {
      "name": "Rituximab",
      "matched_text": "rituximab",
      "compound_id": null,
      "confidence": 0.85,
      "is_investigational": true,
      "phase": "RECRUITING"
    },
    {
      "name": "ADAPT",
      "matched_text": "ADAPT",
      "compound_id": null,
      "confidence": 0.7,
      "is_investigational": false,
      "phase": null
    }
  ],
  "pharma": [
    {
      "name": "Alexion",
      "matched_text": "Alexion Pharmaceuticals",
      "full_name": "Alexion Pharmaceuticals",
      "headquarters": "Boston, USA",
      "parent_company": "AstraZeneca",
      "confidence": 0.95
    },
    {
      "name": "AstraZeneca",
      "matched_text": "AstraZeneca",
      "full_name": "AstraZeneca PLC",
      "headquarters": "Cambridge, UK",
      "parent_company": null,
      "confidence": 0.95
    }
  ]
}